novo nordisk semaglutide stops trial of Ozempic in kidneys as interim analysis shows success Novo Nordisk is proactively protecting

Pfizer still has other candidates in its pipeline

Low-fat, bland choices during nausea flares

But given that the drugs also appear to act on the brains reward system, more direct neurological effects are also plausible

OASIS 4 also found that oral Wegovy significantly outperformed placebo, cutting an average of 13.6% of participants weight, as opposed to 2.4% in the control group

Additionally, it has shown potential neuroprotective and cardioprotective activities in various experimental models, making it a widely explored peptide in tissue repair and regenerative medicine research

In 2024, it repositioned its product line to cater to people taking GLP-1 drugs for weight loss, hoping to attract customers and grow its business